SecBot SecBot
25-NSE ·Filed Jul 13, 2026

ESPR

Esperion Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonimmediate Processed4mo ago SEC0001354457-26-000668
Notable filing: 25-NSE
Actionable Insight ▲ Bullish

The delisting is the final step in the going-private transaction. Shareholders who tendered their shares have already received the $3.16 per share cash consideration plus CVRs. No further trading in ESPR common stock is expected. Monitor CVR milestone events for potential additional value.

DirectionBullish
Confidencehigh
Horizonimmediate
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Esperion Therapeutics has been delisted from Nasdaq following its acquisition by ArchiMed (via Essence Parent Inc.) for $3.16 per share plus CVRs. The 25-NSE filing formalizes the removal of the company's common stock from listing and SEC registration, effective July 13, 2026. This is the final procedural step in the going-private transaction, and the stock will no longer trade on Nasdaq.

Key Facts

  • Esperion Therapeutics completed its acquisition by ArchiMed (via Essence Parent Inc.) on July 13, 2026, for $3.16 per share in cash plus one CVR per share representing up to $100M in aggregate milestone payments.
  • The 25-NSE filing formalizes the removal of Esperion's common stock from listing and registration on Nasdaq, effective July 13, 2026.
  • The delisting follows a change of control, board replacement, and termination of the prior credit agreement with new debt financing from BioPharma Credit.
  • The filing is made under Rule 17 CFR 240.12d2-2(a)(3), which covers securities that have been redeemed, retired, or matured.

Financial Impact

Shareholders received $3.16 per share in cash plus one CVR per share representing up to $100M in aggregate milestone payments. The stock will be delisted and no longer trade on Nasdaq.

stock priceliquiditymarket capitalization

Risk Factors

  • CVR milestone payments are contingent and may not be achieved, resulting in no additional value beyond the $3.16 per share.
  • The stock is now delisted and illiquid; remaining public shareholders must seek liquidity through the merger consideration process.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (Primary)0001354457-26-000668
Document: 0001354457-26-000668-index-headers.html0001354457-26-000668
Document: 0001354457-26-000668-index.html0001354457-26-000668
Document: 0001354457-26-000668.txt0001354457-26-000668

Track record

21 reports on ESPR

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
  2. Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
  3. Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
  4. Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
  5. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  6. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  7. Jul 13, 202618w ago 25-NSE Bullish 7/10 Viewing Entry $3.19 No price data
  8. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
  9. Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
  10. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026